Dengue vaccine research
Dengue is a mosquito-borne flavivirus disease that has spread to most tropical and many subtropical areas. The disease is caused by four closely related viruses, the Dengue viruses 1-4. There are no specific dengue therapeutics and prevention is currently limited to vector control measures. A dengue vaccine would therefore represent a major advance in the control of the disease.
Status of vaccine development
The first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was first registered in Mexico in December, 2015. CYD-TDV is a live recombinant tetravalent dengue vaccine that has been evaluated as a 3-dose series on a 0/6/12 month schedule in Phase III clinical studies. It has been registered for use in individuals 9-45 years of age living in endemic areas.
- Questions and answers on CYD dengue vaccine
- Updated Questions and Answers related to information presented in the Sanofi Pasteur press release on 30 November 2017 with regards to the dengue vaccine Dengvaxia®
WHO recommends that countries should consider introduction of the dengue vaccine CYD-TDV only in geographic settings (national or subnational) where epidemiological data indicate a high burden of disease. Complete recommendations may be found in the WHO position paper on dengue.
WHO position paper on dengue
- Tools to support decision-making for the addition of the licensed dengue vaccine into a public immunization programme
There are approximately five additional vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Additional technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies.
The growing global epidemic of dengue is of mounting concern, and a safe and effective vaccine is urgently needed. WHO expects vaccines to be an integrated part of the Global dengue prevention and control strategy (2012-2020).
Challenges to vaccine development
Infection by one of the four dengue virus serotypes has been shown to confer lasting protection against homotypic re-infection, but only transient protection against a secondary heterotypic infection. Moreover, secondary heterotypic infection is associated with an increased risk of severe disease. This and other observations suggest an immunopathological component in dengue pathogenesis, which is referred to as immune enhancement of disease. Due to these dengue-specific complexities, vaccine development focuses on the generation of a tetravalent vaccine aimed at providing long-term protection against all virus serotypes. Additional challenges are posed by the lack of an adequate animal disease model and the resulting uncertainty around correlates of protection. In spite of these challenges, vaccine development has made remarkable progress in recent years, and the current dengue vaccine pipeline is advanced, diverse and overall promising.
The WHO Initiative for Vaccine Research (IVR), in collaboration with a wide range of partners, aims to facilitate the development and future introduction of safe, effective and affordable dengue vaccines. Activities focus on the following main objectives:
- Identify knowledge gaps and research needs related to the development, evaluation and implementation of dengue vaccines.
- Build scientific consensus and develop guidance on the evaluation of dengue vaccines.
- Review and evaluate the evidence base for policy recommendations related to the introduction and use of dengue vaccines.
- Develop guidance on vaccine implementation, including introduction strategies.
- Support national regulatory authorities in their review of dengue vaccine registration files.
Related WHO guidelines
- Guidelines for the clinical evaluation of dengue vaccines in endemic areas (2008)
- Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses (2007)
- Dengue: Guidelines for diagnosis, treatment, prevention and control (2009)
Related WHO meeting reports
Next generation dengue vaccines (2011)
- Dengue modeling (2011)
- Cell mediated immunity in dengue vaccine development (2008)
- Immune correlates of protection induced by dengue vaccines (2007)
More information on vaccine candidates
Q&A: Phase IIb study of CYD-TDV (September 2012)
- Special Issue: The development of dengue vaccines (Vaccine, Volume 29, Issue 42, Pages 7219-7284, 23 September 2011)
- WHO Technical Advisory Group on Dengue Vaccines in Late Stage Development
- WHO Fact sheet: Dengue and severe dengue
- WHO Global strategy for dengue prevention and control, 2012-2020
- Other WHO activities on dengue
- Dengue Vaccine Initiative (DVI)
- U.S. Centers for Disease Control and Prevention: Dengue Branch